New long-term safety data from the completed phase 3 solaris trial support the potential of olanzapine lai (tev-'749) as the first long-acting olanzapine treatment option for schizophrenia with no pdss observed

Parsippany, n.j., and tel aviv, israel, sept. 20, 2025 (globe newswire) -- teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced the presentation of 10 posters from its innovative schizophrenia medicines portfolio, including long-term safety data from the completed solaris phase 3 trial showing no incidence of post-injection delirium/sedation syndrome (pdss) in study participants taking olanzapine lai (tev-'749), a once-monthly, long-acting injectable (lai) subcutaneous formulation of olanzapine.1 new data evaluating uzedy®, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults, found that it was associated with a shorter length of hospitalization compared to a once-monthly intramuscular injection of invega sustenna®.1 no comparisons can be made regarding efficacy, safety, or any other clinical outcomes as this was not studied. the data were presented at the 2025 psych congress annual meeting, taking place from september 17–21, 2025, in san diego, california.
TEVA Ratings Summary
TEVA Quant Ranking